Search Result

Results for "

Mek

" in MedChemExpress (MCE) Product Catalog:

By Targets:	MEK (204) 5-HT Receptor (4) Akt (32) AMPK (2) Amyloid-β (2) Anaplastic lymphoma kinase (ALK) (2) Antibiotic (1) AP-1 (2) Apoptosis (86) Aryl Hydrocarbon Receptor (2) Aurora Kinase (3) Autophagy (26) Bacterial (2) Bcl-2 Family (4) Beta-secretase (2) Btk (1) c-Fms (1) c-Met/HGFR (1) Cadherin (2) Calcium Channel (3) CaMK (1) Casein Kinase (1) Caspase (8) Cathepsin (1) CDK (8) Checkpoint Kinase (Chk) (1) Cholinesterase (ChE) (2) COX (4) Cyclin G-associated Kinase (GAK) (1) DNA/RNA Synthesis (2) Dopamine Receptor (3) Drug Derivative (1) E-Selectin (4) E3 Ligase Ligand-Linker Conjugates (2) EGFR (7) Endogenous Metabolite (11) Environmental Pollutants (2) Epigenetic Reader Domain (1) ERK (81) Estrogen Receptor/ERR (2) FAK (1) Ferroptosis (3) FGFR (1) FLT3 (4) GLP Receptor (3) Glutathione S-transferase (2) GPR55 (1) GSK-3 (2) HBV (1) HCV (1) HDAC (2) Heme Oxygenase (HO) (1) Herbicide (2) HIF/HIF Prolyl-Hydroxylase (2) HIV (3) HSP (1) IFNAR (1) IGF-1R (1) Influenza Virus (3) Insulin Receptor (1) Interleukin Related (5) Isotope-Labeled Compounds (12) JAK (3) JNK (8) Keap1-Nrf2 (2) Ligands for Target Protein for PROTAC (2) MAP3K (2) MDM-2/p53 (3) Microtubule/Tubulin (2) Mitochondrial Metabolism (1) Mitophagy (5) Mixed Lineage Kinase (1) MMP (11) Molecular Glues (2) mTOR (4) NF-κB (25) NO Synthase (1) NOD-like Receptor (NLR) (4) P-glycoprotein (1) P2Y Receptor (1) p38 MAPK (22) PAK (2) Parasite (2) PARP (5) PD-1/PD-L1 (1) PDGFR (2) PDK-1 (1) PERK (10) PGC-1α (1) Phosphatase (1) PI3K (26) Pim (1) PKA (1) PKC (8) Potassium Channel (1) PPAR (2) PROTACs (7) PTEN (1) Raf (21) Ras (15) Reactive Oxygen Species (ROS) (13) Reference Standards (31) Ribosomal S6 Kinase (RSK) (1) RIP kinase (1) ROCK (1) SARS-CoV (2) SHP2 (1) Small Interfering RNA (siRNA) (2) Smo (1) SOD (1) Sodium Channel (11) SOS1 (1) Src (6) STAT (6) Syk (1) Tau Protein (1) TGF-beta/Smad (1) Tie (1) TNF Receptor (6) Toll-like Receptor (TLR) (2) Topoisomerase (1) Trk Receptor (4) ULK (1) VEGFR (10) Wnt (2) Xanthine Oxidase (1) YAP (2) β-catenin (1)
By Research Areas:	Cancer (228) Cardiovascular Disease (29) Infection (10) Inflammation/Immunology (42) Metabolic Disease (22) Neurological Disease (34)
Oligonucleotides:	Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (1) siRNAs (2)

274

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Oligonucleotides

GMP Molecules

Targets Recommended: MEK ASK1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10999

Trametinib 285+ Cited Publications GSK1120212; JTP-74057	MEK Autophagy Apoptosis	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Trametinib (GSK1120212; JTP-74057) is an orally active *MEK* inhibitor that inhibits MEK1 and MEK2 with IC₅₀s of about 2 nM. Trametinib activates autophagy and induces apoptosis, cross the blood-brain barrier (BBB), used in research related to subarachnoid hemorrhage (SAH) .

HY-10254

Mirdametinib 150+ Cited Publications PD0325901; PD325901	MEK Autophagy Apoptosis	Cancer
Mirdametinib (PD0325901) is an orally active, selective and non-ATP-competitive *MEK* inhibitor with an IC₅₀ of 0.33 nM. Mirdametinib exhibits a K_i ^app of 1 nM against activated MEK1 and MEK2. Mirdametinib suppresses the expression of p-ERK1/2 and induces apoptosis. Mirdametinib has anti-cancer activity for a broad spectrum of human tumor xenografts .

HY-12031A

U0126 Maximum Cited Publications 459 Publications Verification	MEK Autophagy Mitophagy Influenza Virus	Cancer
U0126 is a potent, non-ATP competitive and selective *MEK1* and *MEK2* inhibitor, with IC₅₀s of 72 nM and 58 nM, respectively. U0126 is an autophagy and mitophagy inhibitor .

HY-50706

Selumetinib 85+ Cited Publications AZD6244; ARRY-142886	MEK Apoptosis	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Selumetinib (AZD6244) is selective, non-ATP-competitive oral *MEK1/2* inhibitor, with an IC₅₀ of 14 nM for MEK1. Selumetinib (AZD6244) inhibits ERK1/2 phosphorylation. Selumetinib can penetrate the blood brain barrier (BBB) .

HY-15202

Binimetinib 45+ Cited Publications Mek162; ARRY-162; ARRY-438162	MEK Autophagy	Cancer
Binimetinib (MEK162) is an oral and selective *MEK1/2* inhibitor. Binimetinib (MEK162) inhibits *MEK* with an IC₅₀ of 12 nM.

HY-13064

Cobimetinib 60+ Cited Publications GDC-0973; XL518	MEK Apoptosis	Cancer
Cobimetinib (GDC-0973, RG7420) is a potent, selective and oral *MEK1* inhibitor with an IC₅₀ of 4.2 nM for *MEK1*.

HY-12028

PD98059 390+ Cited Publications	MEK ERK Aryl Hydrocarbon Receptor Autophagy	Cancer
PD98059 is a potent and selective *MEK* inhibitor with an IC₅₀ of 5 µM. PD98059 binds to the inactive form of *MEK, thereby preventing the activation of MEK1* (IC₅₀ of 2-7 µM) and *MEK2* (IC₅₀ of 50 µM) by upstream kinases. PD98059 is a ERK1/2 signaling inhibitor. PD98059 is a ligand for the aryl hydrocarbon receptor (AHR), and suppresses TCDD binding (IC₅₀ of 4 μM) and AHR transformation (IC₅₀ of 1 μM). PD98059 also inhibits Mycobacterium bovis Bacillus CalmetteGuerin (BCG)-induced autophagy .

HY-18652

Avutometinib 4 Publications Verification Ro 5126766; CH5126766	MEK Raf	Cancer
Avutometinib (Ro 5126766) is a first-in-class dual *MEK/RAF* inhibitor that allosterically inhibits BRAF ^V600E, CRAF, *MEK, and BRAF* (IC₅₀: 8.2, 56, 160 nM, and 190 nM, respectively).

HY-15610

GDC-0623 5+ Cited Publications RG 7421; Mek inhibitor 1	MEK Apoptosis	Cancer
GDC-0623 (RG 7421) is a potent, ATP-uncompetitive inhibitor of *MEK1* (K_i=0.13 nM, +ATP), and displays 6-fold weaker potency against HCT116 (KRAS (G13D), EC₅₀=42 nM) versus A375 (BRAF ^V600E, EC₅₀=7 nM).

HY-50295

CI-1040 20+ Cited Publications PD 184352	MEK Apoptosis	Cancer
CI-1040 (PD 184352) is an orally active, highly specific, small-molecule inhibitor of *MEK* with an IC₅₀ of 17 nM for MEK1.

HY-10999A

Trametinib (DMSO solvate) 285+ Cited Publications GSK-1120212 (DMSO solvate); JTP-74057 (DMSO solvate)	MEK Apoptosis	Cancer
Trametinib (DMSO solvate) (GSK-1120212 (DMSO solvate)) is an orally active *MEK* inhibitor that inhibits MEK1 and MEK2 with IC₅₀s of about 2 nM. Trametinib (DMSO solvate) activates autophagy and induces apoptosis . This product is in solid form, a DMSO solvate, and a stable crystalline form.

HY-12058

AZD8330 5+ Cited Publications ARRY-424704; ARRY-704	MEK	Cancer
AZD8330 (ARRY-424704) is a potent, uncompetitive *MEK1/MEK2* inhibitor, with an IC₅₀ of 7 nM.

HY-172415

Atebimetinib IMM-1-104	MEK	Cancer
Atebimetinib (IMM-1-104) is a novel orally dual-MEK inhibitor with anti-pancreatic cancer activity .

HY-12042

Pimasertib 5+ Cited Publications AS703026; MSC1936369B	MEK	Cancer
Pimasertib (AS703026) is a highly selective, ATP non-competitive allosteric orally available *MEK1/2* inhibitor .

HY-153181

Trametiglue 1 Publications Verification	MEK	Cancer
Trametiglue, a derivative of Trametinib (HY-10999), targets both *KSR-MEK* and *RAF-MEK* with unprecedented potency and selectivity via unique interfacial binding interactions .

HY-14691

Refametinib 10+ Cited Publications BAY 869766; RDEA119	MEK	Cancer
Refametinib (BAY 869766; RDEA119) is an orally available, potent, non-ATP-competitive, selective, allosteric *MEK1/MEK2* inhibitor with IC₅₀s of 19 nM and 47 nM, respectively.

HY-50706A

Selumetinib sulfate 85+ Cited Publications AZD6244 sulfate; ARRY-142886 sulfate	MEK Apoptosis	Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Selumetinib (AZD6244) sulfate is selective, non-ATP-competitive oral *MEK1/2* inhibitor, with an IC₅₀ of 14 nM for MEK1. Selumetinib (AZD6244) sulfate inhibits ERK1/2 phosphorylation. Selumetinib sulfate can penetrate the blood brain barrier (BBB) .

HY-12202

MEK inhibitor 2 Publications Verification	MEK	Cancer
MEK inhibitor is a potent *MEK* inhibitor with antitumor potency.

HY-13064A

Cobimetinib hemifumarate 60+ Cited Publications GDC-0973 hemifumarate; XL-518 hemifumarate	MEK Apoptosis	Cancer
Cobimetinib hemifumarate is a novel selective *MEK1* inhibitor, and the IC₅₀ value against MEK1 is 4.2 nM.

HY-14719

RO4987655 5+ Cited Publications CH4987655	MEK	Cancer
RO4987655 is an orally active and highly selective *MEK* inhibitor with an IC₅₀ of 5.2 nM for inhibition of *MEK1/MEK2*.

HY-18086

TCS PIM-1 1 4 Publications Verification SC 204330	Pim	Cancer
TCS PIM-1 1 (SC 204330) is a potent, selective and ATP-competitive Pim-1 kianse inhibitor with an IC₅₀ of 50 nM, displays good selectivity over Pim-2 and MEK1/MEK2 (IC₅₀s >20000 nM) .

HY-15437

SL327 5+ Cited Publications	MEK	Cancer
SL327 inhibits *MEK1* and *MEK2, with IC₅₀* values of 180 nM and 220 nM, respectively.

HY-12062

PD318088 1 Publications Verification	MEK	Cancer
PD318088 is a potent, allosteric and non-ATP competitive *MEK1/2* inhibitor, an analog of PD184352 (HY-50295). PD318088 binds simultaneously with ATP in a region of the MEK1 active site that is adjacent to the ATP-binding site. PD318088 can be used for cancer research .

HY-100627

APS-2-79	MEK	Cancer
APS-2-79 is a KSR-dependent *MEK* antagonist. APS-2-79 inhibits ATP ^biotin binding to KSR2 within the KSR2-MEK1 complexe with an IC₅₀ of 120 nM. APS-2-79 makes the stabilization of the KSR inactive state antagonizes oncogenic Ras-MAPK signaling .

HY-107620

PD 198306	MEK	Neurological Disease
PD 198306 is a selective MAPK/ERK-kinase (MEK) inhibitor. PD 198306 results in an observable reduction in the Streptozocin induced increase in the level of active ERK1 and 2. Antihyperalgesic effects .

HY-130602

MS432	PROTACs MEK	Cancer
MS432 is a first-in-class and highly selective PD0325901-based von Hippel-Lindau-recruiting PROTAC degrader for *MEK1* and *MEK2. MS432 displays good plasma exposure in mice, exhibiting DC₅₀* values of 31 nM and 17 nM for MEK1, MEK2 in HT29 cells respectively .

HY-10999R

Trametinib (Standard) GSK1120212 (Standard); JTP-74057 (Standard)	Reference Standards MEK Autophagy Apoptosis	Cancer
Trametinib (Standard) is the analytical standard of Trametinib. This product is intended for research and analytical applications. Trametinib (GSK1120212; JTP-74057) is an orally active *MEK* inhibitor that inhibits MEK1 and MEK2 with IC₅₀s of about 2 nM. Trametinib activates autophagy and induces apoptosis .

HY-12055

BIX02188 3 Publications Verification	MEK ERK	Cancer
BIX02188 is a potent *MEK5*-selective inhibitor with an IC₅₀ of 4.3 nM. BIX02188 inhibits ERK5 catalytic activity, with an IC₅₀ of 810 nM.

HY-153863

MS934	PROTACs MEK Raf	Cancer
MS934 is a novel improved VHL-recruiting MEK 1/2 PROTAC degrader. MS934 also degrades CRAF. MS934 can be used for the research of variety of human cancers, such as melanoma, nonsmall cell lung cancer (NSCLC), colorectal cancer, primary brain tumors, and hepatocellular carcinoma (Pink: Target protein ligand (HY-168288); Black: linker (HY-168289); Blue: E3 ligase ligand (HY-112078)) .

HY-153864

*PROTAC MEK1 Degrader-1*	PROTACs MEK ERK	Cancer
PROTAC MEK1 Degrader-1 is a PROTAC targeting *MEK1* with a pIC₅₀ value of 7.0. PROTAC MEK1 Degrader-1 consists of a *MEK1* inhibitor and a von Hippel-Lindau ligand. PROTAC MEK1 Degrader-1 can inhibit ERK1/2 phosphorylation. PROTAC MEK1 Degrader-1 shows an antiproliferative activity against A375 cells .

HY-145702

MAP855	MEK ERK	Cancer
MAP855 is a highly potent, selective, ATP-competitive and orally active *MEK1/2* kinase inhibitor (MEK1 ERK2 cascade IC₅₀=3 nM, pERK EC₅₀=5 nM). MAP855 shows equipotent inhibition of wild-type and mutant MEK1/2 .

HY-10999S

Trametinib-d4	MEK Autophagy Apoptosis	Cancer
Trametinib-d₄ is the deuterium labeled Trametinib. Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC₅₀s of about 2 nM. Trametinib activates autophagy and induces apoptosis .

HY-153445

Polfurmetinib 1 Publications Verification Mek-IN-6	ERK MEK	Cancer
Polfurmetinib (MEK-IN-6) (Example 69) is a *MEK* inhibitor. MEK-IN-6 inhibits ERK1/2 (Thr202/Tyr204) phosphorylation in A375 cells (IC₅₀: 2 nM). Polfurmetinib can be used for research of cancer .

HY-163173

TEAD-IN-8	YAP	Cancer
TEAD-IN-8 is a novel TEAD inhibitor, which potently and specifically inhibits TEAD-YAP transcriptional activities. TM2, alone or in combination with MEK inhibitors, exhibits potent antiproliferative effects in YAP-dependent cancer cells .

HY-N13009

MO-2097	Raf HIF/HIF Prolyl-Hydroxylase ERK MEK Reactive Oxygen Species (ROS) Apoptosis Caspase	Cancer
MO-2097 is a RAF-1/HIF-1α inhibitor. MO-2097 induces RAF-1 destabilization, leading to a reduction in EMT-associated transcription factors and mesenchymal markers. MO-2097 inhibits HIF-1a protein expression mediated by hnRNPA2B1 under hypoxic and mimetic hypoxia. MO-2097 induces mitochondrial ROS, which leads to apoptosis in cells. MO-2097 effectively suppresses colorectal cancer metastasis by inhibiting the *RAF/MEK/ERK* signaling pathway. MO-2097 attenuates tumor growth in a xenograft HCT116 cell mouse model. MO-2097 can be used for the study of colorectal cancer .

HY-146127

Grb2 SH2 domain inhibitor 1	MEK	Cancer
Grb2 SH2 domain inhibitor 1 is an inhibitor of the Grb2 SH2 domain with an IC₅₀ of 0.40 μM. Grb2 SH2 domain inhibitor 1 is also a cell-permeable cyclic peptide that can enter the cytosol of mammalian cells. Grb2 SH2 domain inhibitor 1 downregulates the expression level of *p-MEK*. Grb2 SH2 domain inhibitor 1 can be used in the research of breast cancer .

HY-131295

PD0325901-O-C2-dioxolane 2 Publications Verification	MEK Ligands for Target Protein for PROTAC	Cancer
PD0325901-O-C2-dioxolane has main portion of *MEK* inhibitor PD0325901. PD0325901-O-C2-dioxolane and a ligand of VHL or CRBN E3 ligase can be used in the synthesis of MEK1/2 degrader .

HY-107621

U0124	MEK	Cancer
U0124, an inactive U0126 analog, has no effect on c-Fos and c-Jun protein or mRNA levels. U0126 is a MEK inhibitor. U0124 does not inhibit MEK at concentrations up to 100 μM .

HY-107417

Hypothemycin	VEGFR MEK FLT3 PDGFR ERK	Cancer
Hypothemycin, a fungal polyketide, is a multikinase inhibitor with K_is of 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for VEGFR2/VEGFR1, *MEK1/MEK2, FLT-3, PDGFRβ/PDGFRα, and ERK1/ERK2*, respectively .

HY-13064S1

Cobimetinib-d4 hydrochloride GDC-0973-d4hydrochloride; XL518-d4 hydrochloride	MEK Apoptosis Isotope-Labeled Compounds	Cancer
Cobimetinib-d₄ hydrochloride is deuterated labeled Cobimetinib (HY-13064). Cobimetinib (GDC-0973, RG7420) is a potent, selective and oral *MEK1* inhibitor with an IC₅₀ of 4.2 nM for *MEK1*.

HY-137881

MEK-IN-4	MEK	Inflammation/Immunology Cancer
MEK-IN-4 is a *MEK* inhibitor. MEK-IN-4 can be used for the research of inflammatory disorders and cancers .

HY-139638

MEK4 inhibitor-1	MEK	Cancer
MEK4 inhibitor-1 is a novel *MEK4* inhibitor against pancreatic adenocarcinoma with an IC₅₀ value of 61 nM.

HY-139639

MEK4 inhibitor-2	MEK	Cancer
MEK4 inhibitor-2 is a novel *MEK4* inhibitor against pancreatic adenocarcinoma with an IC₅₀ value of 83 nM.

HY-P4133

MEK1 Derived Peptide Inhibitor 1	ERK MEK	Cancer
MEK1 Derived Peptide Inhibitor 1 is a peptide inhibitor. MEK1 Derived Peptide Inhibitor 1 can inhibit the in vitro activation of ERK2 by *MEK1* with an IC₅₀ value of 30 μM. MEK1 Derived Peptide Inhibitor 1 can be used for the research of cell-permeable .

HY-170982

MS910	MEK PROTACs	Cancer
MS910 is an efficient and selective MEK1/2 PROTAC degrader. MS910 exhibits effective MEK1/2 degradation ability and anti proliferative activity in various cancer cells, such as HT-29 (MEK1 DC₅₀ = 118 nM, MEK2 DC₅₀ = 55 nM) and SK-MEL-28 (MEK1 DC₅₀ = 94 nM, MEK2 DC₅₀ = 38 nM) cells. MS910 is commonly used in cancer research. (Pink: MEK1/2 Ligand (HY-10254); Blue: CRBN Ligand (HY-W087383); Black: Linker (HY-W022240))

HY-10999S1

Trametinib-13C6	MEK Autophagy Apoptosis	Cancer
Trametinib- ¹³C₆ is the ¹³C-labeled Trametinib. Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC₅₀s of about 2 nM. Trametinib activates autophagy and induces apoptosis .

HY-100627A

APS-2-79 hydrochloride	MEK	Cancer
APS-2-79 hydrochloride is a KSR-dependent *MEK* antagonist. APS-2-79 inhibits ATP ^biotin binding to KSR2 within the KSR2-MEK1 complexe with an IC₅₀ of 120 nM. APS-2-79 makes the stabilization of the KSR inactive state antagonizes oncogenic Ras-MAPK signaling .

HY-177914

MEK-IN-7	MEK	Cancer
MEK-IN-7 (compound WX086) is potent, orally active and selective *MEK* inhibitor (MEK1 IC₅₀ = 29.62 nM). MEK-IN-7 inhibits HT29 and A375 cell proliferation with IC₅₀s of 0.62 and 0.40 nM. MEK-IN-7 inhibits tumor growth in a HL-29 xenograft mouse model. MEK-IN-7 can be used for melanoma and colon cancer research .

HY-179909

MEK-IN-9	MEK CDK	Cancer
MEK-IN-9 (Compound 4-82) is a *MEK* inhibitor. MEK-IN-9 induces p15 and p27 protein. MEK-IN-9 can be used in the research of renal adenocarcinoma and colorectal cancer .

HY-179908

MEK-IN-8	MEK	Cancer
MEK-IN-8 (Compound 30) is a *MEK* inhibitor (IC₅₀: < 5 nM for pMEK in A549 cells). MEK-IN-8 can be used in tumor research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-14590

Kaempferol Maximum Cited Publications 76 Publications Verification Kempferol; Robigenin	Flavonols Classification of Application Fields Anti-aging Plants Endogenous metabolite Human Gut Microbiota Metabolites Flavonoids Microorganisms other families Sunscreen Phenols Polyphenols Cosmetic Research Disease Research Fields Source Classification Cancer	Estrogen Receptor/ERR Autophagy Mitophagy Apoptosis HIV Parasite Endogenous Metabolite
Kaempferol (Kempferol), a flavonoid found in many edible plants, inhibits estrogen receptor α expression in breast cancer cells and induces apoptosis in glioblastoma cells and lung cancer cells by activation of MEK-MAPK. Kaempferol can be uesd for the research of breast cancer .

HY-N0776

Isorhamnetin 15+ Cited Publications 3'-Methylquercetin	Cardiovascular Disease Flavonols Classification of Application Fields Hippophaë rhamnoides Plants Endogenous metabolite Flavonoids Microorganisms Leguminosae Elaeagnaceae Phenols Polyphenols Glycyrrhiza uralensis Fisch. Inflammation/Immunology Disease Research Fields Source Classification	MEK PI3K Endogenous Metabolite
Isorhamnetin is a flavonoid compound extracted from the Chinese herb Hippophae rhamnoides L.. Isorhamnetin suppresses skin cancer through direct inhibition of *MEK1* and PI3K.

HY-108635

C16-PAF 35+ Cited Publications PAF (C16)	Natural Products Human Gut Microbiota Metabolites Classification of Application Fields Endogenous metabolite Inflammation/Immunology Disease Research Fields Source Classification	p38 MAPK MEK ERK Endogenous Metabolite
C16-PAF (PAF (C16)), a phospholipid mediator, is a platelet-activating factor and ligand for PAF G-protein-coupled receptor (PAFR). C16-PAF exhibits anti-apoptotic effect and inhibits caspase-dependent death by activating the PAFR. C16-PAF is a potent MAPK and *MEK/ERK* activator. C16-PAF induces increased vascular permeability .

HY-19700

trans-Zeatin 3 Publications Verification	Structural Classification Natural Products Zea mays L. Classification of Application Fields Plants Endogenous metabolite Cytokinin Agricultural Research Gramineae Other Diseases Phytohormone Disease Research Fields Source Classification	Environmental Pollutants Endogenous Metabolite MEK ERK
trans-Zeatin is a plant cytokinin, which plays an important role in cell growth, differentiation, and division; trans-Zeatin also inhibits UV-induced *MEK/ERK* activation.

HY-N0103

Sophocarpine 10+ Cited Publications	Infection Alkaloids Piperidine Alkaloids Classification of Application Fields Leguminosae Sophora flavescens Aiton Plants Inflammation/Immunology Disease Research Fields Source Classification	Autophagy Apoptosis NF-κB PI3K Akt MEK ERK PTEN
Sophocarpine is a PTEN activator and an inhibitor of PI3K/Akt, MEK/ERK, and NF-κB signaling pathways. Sophocarpine upregulates PTEN expression and inhibits PI3K/Akt phosphorylation, arrests tumor cell cycle and induces apoptosis. Sophocarpine inhibits MEK/ERK phosphorylation and VEGF secretion, reducing tumor cell migration. Sophocarpine can also inhibit NF-κB activation and p38 and JNK phosphorylation, reduce the expression of inflammatory factors such as iNOS and COX-2, and activate the Nrf2/HO-1 pathway to reduce oxidative stress. Sophocarpine has anti-tumor, anti-inflammatory, antioxidant and anti-apoptotic effects, and can be used in the research of cancers such as glioblastoma and colorectal cancer, inflammation-related diseases, and Doxorubicin (HY-15142A)-induced cardiac damage .

HY-13425

Deguelin 10+ Cited Publications (-)-Deguelin; (-)-cis-Deguelin	Flavonoids Classification of Application Fields Leguminosae Isoflavanones Derris trifoliata Lour. Plants Disease Research Fields Biological Pesticide Research Source Classification Cancer Agricultural Research	Akt Autophagy Apoptosis
Deguelin, a naturally occurring rotenoid, acts as a chemopreventive agent by blocking multiple pathways like PI3K-Akt, IKK-NF-κB, and MAPK-mTOR-survivin-mediated apoptosis. Deguelin binding to Hsp90 leads to a decreased expression of numerous oncogenic proteins, including MEK1/2, Akt, HIF1α, COX-2, and NF-κB.

HY-14590R

Kaempferol (Standard) Maximum Cited Publications 76 Publications Verification Kempferol(Standard); Robigenin (Standard)	Classification of Application Fields Anti-aging Plants Endogenous metabolite Human Gut Microbiota Metabolites Flavonoids other families Sunscreen Phenols Cosmetic Research Disease Research Fields Source Classification Cancer	Reference Standards Estrogen Receptor/ERR Autophagy Mitophagy Apoptosis HIV Parasite Endogenous Metabolite
Kaempferol (Standard) is the analytical standard of Kaempferol. This product is intended for research and analytical applications. Kaempferol (Kempferol), a flavonoid found in many edible plants, inhibits estrogen receptor α expression in breast cancer cells and induces apoptosis in glioblastoma cells and lung cancer cells by activation of MEK-MAPK. Kaempferol can be uesd for the research of breast cancer .

HY-N0226A

Epiberberine chloride 4 Publications Verification	Alkaloids Neurological Disease Classification of Application Fields Coptis chinensis Franch. Ranunculaceae Metabolic Disease Plants Isoquinoline Alkaloids Disease Research Fields Source Classification	Cholinesterase (ChE) Beta-secretase Reactive Oxygen Species (ROS)
Epiberberine chloride is an alkaloid isolated from Coptis chinensis, acts as a potent AChE and BChE inhibitor, and a non-competitive BACE1 inhibitor, with IC₅₀s of 1.07, 6.03 and 8.55 μM, respectively. Epiberberine chloride has antioxidant activity, with peroxynitrite ONOO ^- scavenging effect (IC₅₀, 16.83 μM), and may protect against Alzheimer disease . Epiberberine chloride inhibits the early stage of differentiation of 3T3-L1 preadipocytes, downregulates the Raf/MEK1/2/ERK1/2 and AMPKα/Akt pathways . Epiberberine has the potential effect in the research of diabetic disease .

HY-12316

20(S)-Hydroxycholesterol 3 Publications Verification 20α-Hydroxycholesterol	Classification of Application Fields Endogenous metabolite Disease Research Fields Steroids Source Classification Cancer	Smo Endogenous Metabolite
20(S)-Hydroxycholesterol (20α-Hydroxycholesterol) is an allosteric activator that selectively targets the Smoothened (Smo) of the Hedgehog pathway with an EC₅₀ of ~30 μM (Hedgehog). 20(S)-Hydroxycholesterol binds to the extracellular cysteine-rich domain (CRD) of Smo in a stereoselective manner, activating downstream Gli transcription factors (without inducing transcription of receptor genes in the Wnt pathway). 20(S)-Hydroxycholesterol enhances osteogenic differentiation of bone marrow stromal cells and synergistically activates the *Raf/MEK/ERK* pathway with Simvastatin (HY-17502) to promote bone regeneration. 20(S)-Hydroxycholesterol can be used to study the mechanisms of developmental biology, oncology, bone, and angiogenesis .

HY-N0226

Epiberberine	Alkaloids Structural Classification Coptis chinensis Franch. Ranunculaceae Plants Isoquinoline Alkaloids Source Classification	Cholinesterase (ChE) Beta-secretase
Epiberberine is an alkaloid isolated from Coptis chinensis, acts as a potent AChE and BChE inhibitor, and a non-competitive BACE1 inhibitor, with IC₅₀s of 1.07, 6.03 and 8.55 μM, respectively. Epiberberine has antioxidant activity, with peroxynitrite ONOO ^- scavenging effect (IC₅₀, 16.83 μM), and can be used for the research of Alzheimer disease . Epiberberine inhibits the early stage of differentiation of 3T3-L1 preadipocytes, downregulates the Raf/MEK1/2/ERK1/2 and AMPKα/Akt pathways . Epiberberinecan be used for the research of diabetic disease .

HY-N9330

Broussoflavonol F	Flavonols Structural Classification Flavonoids other families Classification of Application Fields Other Diseases Phenols Polyphenols Plants Disease Research Fields Source Classification	Xanthine Oxidase
Broussoflavonol F is a *HER2-RAS-MEK-ERK* signaling pathway modulator and mushroom tyrosinase inhibitor, with an IC₅₀ of 82.3 μM against mushroom tyrosinase. Broussoflavonol F reduces the protein expression levels of RAS, HER2, phosphorylated BRAF, phosphorylated MEK and phosphorylated Erk. It induces cell apoptosis, triggers G₀/G₁ phase cell cycle arrest, and exhibits cytotoxicity against colon cancer cells. Broussoflavonol F is applicable to related research on colon cancer .

HY-128393

Trilinolein 1 Publications Verification	Natural Products Panax notoginseng (Burkill) F. H. Chen ex C. H. Chow Classification of Application Fields Metabolic Disease Plants Endogenous metabolite Disease Research Fields Araliaceae Source Classification	PI3K Akt E-Selectin Apoptosis MMP MEK ERK
Trilinolein is an orally active triglyceride that inhibits the PI3K/Akt, *Ras/MEK/ERK* signaling pathways, and MMP-2. Trilinolein can reduce oxidative stress, induce apoptosis, and inhibit cell migration. Trilinolein can be used in the research fields of cardiovascular disease, cerebrovascular disease (such as cerebral ischemia), and non-small cell lung cancer .

HY-107207

Kaempferol 3-neohesperidoside 3 Publications Verification Kaempferol 3-O-neohesperidoside	Flavonols Structural Classification Flavonoids Typhaceae Classification of Application Fields Typha orientalis Presl Phenols Polyphenols Metabolic Disease Plants Disease Research Fields Source Classification	Insulin Receptor PI3K PKC
Kaempferol 3-neohesperidoside (Kaempferol 3-O-neohesperidoside) is a flavonoid. Kaempferol 3-neohesperidoside mimics insulin action via the PI3K/PKC pathway, significantly promoting glucose uptake and increasing muscle glycogen content in rat soleus muscles. Kaempferol 3-neohesperidoside also exhibits anti-glycation activity. Kaempferol 3-neohesperidoside binds to albumin through hydrogen bonding and hydrophobic interactions, and inhibits the formation of advanced glycation end products. Kaempferol 3-neohesperidoside can be used in studies of diabetes and its related complications .

HY-N0392

Polygalasaponin F	Triterpenes Structural Classification Classification of Application Fields Terpenoids Polygalaceae Polygala japonica Houtt. Plants Inflammation/Immunology Disease Research Fields Source Classification	Toll-like Receptor (TLR) PI3K Akt NF-κB MDM-2/p53 Caspase MEK Bcl-2 Family p38 MAPK Mitophagy Reactive Oxygen Species (ROS) Apoptosis Calcium Channel
Polygalasaponin F is an orally active triterpenoid saponin monomer. Polygalasaponin F downregulates the expression of Bax, p53, caspase-3, NF-κB p65 and *MEK1; restores and upregulates the expression of Bcl-2; activates the PI3K/Akt* signaling pathway; inhibits the phosphorylation of p38 MAPK, nuclear translocation of NF-κB, TLR4-mediated signaling pathway, mitophagy (Mitophagy) and ROS production; enhances cell viability and suppresses apoptosis (Apoptosis). Polygalasaponin F maintains mitochondrial function, alleviates Ca ²⁺ overload, upregulates pCREB and BDNF, preserves cell viability and inhibits the release of inflammatory cytokines. Polygalasaponin F alleviates lung injury induced by influenza A H1N1 and cerebral ischemia-reperfusion injury. Polygalasaponin F is applicable to researches related to Parkinson's disease, cerebral ischemia, pneumonia induced by influenza A H1N1, stroke and Alzheimer's disease .

HY-N0442

5-O-Methylvisammioside 4'-O-β-D-Glucosyl-5-O-methylvisamminol	Structural Classification Ophryosporus axilliflorus Hieron. Classification of Application Fields Ketones, Aldehydes, Acids Other Diseases Umbelliferae Plants Disease Research Fields Source Classification	NF-κB p38 MAPK JNK Src TNF Receptor NOD-like Receptor (NLR) Amyloid-β MEK ERK Ferroptosis VEGFR Anaplastic lymphoma kinase (ALK) Reactive Oxygen Species (ROS)
5-O-Methylvisammioside (4'-O-β-D-Glucosyl-5-O-methylvisamminol) is an orally active natural chromone glycoside and multiple biological activities. 5-O-Methylvisammioside inhibits ferroptosis by activating the Nrf2/HO-1 signaling axis. 5-O-Methylvisammioside alleviates intestinal barrier damage by inhibiting the ROS/NF-κB/NLRP3 pathway. 5-O-Methylvisammioside exerts a protective effect against acute liver injury by reducing ALT/AST, decreasing inflammatory infiltration, and inhibiting IκB-α phosphorylation and NF-κB nuclear translocation. 5-O-Methylvisammioside blocks the *HMGB1/RAGE/MEK/ERK* signaling axis to exert anti-tumor and anti-angiogenic effects. 5-O-Methylvisammioside improves depression-like behaviors by inhibiting Src kinase and the NF-κB pathway .

HY-N0909

Notoginsenoside R2 1 Publications Verification 20(S)-Notoginsenoside R2; Ginsenoside Ng-R2	Triterpenes Structural Classification Panax notoginseng (Burkill) F. H. Chen ex C. H. Chow Neurological Disease Classification of Application Fields Terpenoids Plants Disease Research Fields Araliaceae Source Classification	Apoptosis MEK ERK Reactive Oxygen Species (ROS) Caspase COX β-catenin Src MDM-2/p53 JAK STAT
Notoginsenoside R2 (20(S)-Notoginsenoside R2; Ginsenoside Ng-R2) is an orally active notoginsenoside . Notoginsenoside R2 activates P90RSK and Nrf2 via the *MEK1/2-ERK1/2* pathway to inhibit 6-OHDA-induced apoptotic damage in nerve cells. Notoginsenoside R2 upregulates SOX8/β-catenin by reducing miR-27a, thereby suppressing Aβ_25-35-induced neuronal apoptosis and inflammatory responses . Notoginsenoside R2 alleviates lipid accumulation and mitochondrial dysfunction in diabetic nephropathy by inhibiting c-Src. Notoginsenoside R2 alleviates hepatic fibrosis by inducing hepatic stellate cell senescence and inhibiting the inflammatory microenvironment via JAK/STAT3 suppression . Notoginsenoside R2 can be used in research related to Parkinson's disease, Alzheimer's disease, diabetic nephropathy and hepatic fibrosis .

HY-N12445

Quercetin-3'-O-glucoside 1 Publications Verification	Malvaceae Structural Classification Flavonols Flavonoids Abelmoschus manihot (Linn.) Medicus Plants Source Classification	Topoisomerase Caspase Apoptosis SOD
Quercetin-3'-O-glucoside is an orally active flavonoid glycoside. Quercetin-3'-O-glucoside reduces liver glucose-6-phosphatase activity, alters serum insulin and glucose levels, and regulates the activities of antioxidant enzymes in the liver and kidney. Quercetin-3'-O-glucoside inhibits DNA topoisomerase II, induces S-phase cell cycle arrest and caspase-3-mediated apoptosis in hepatocellular carcinoma cells. Quercetin-3'-O-glucoside selectively inhibits EGFR-mediated signaling pathways targeting AKT, ERK1/2, FAK and MEK1/2. Quercetin-3'-O-glucoside inhibits growth factor-induced migration and invasion in pancreatic cancer cells. Quercetin-3'-O-glucoside exerts free radical scavenging effects. Quercetin-3'-O-glucoside is applicable to research related to pancreatic cancer, diabetes, hepatocellular carcinoma and malignant tumors .

HY-N13009

MO-2097	Phenols Polyphenols Morus alba L. Plants Moraceae Source Classification	Raf HIF/HIF Prolyl-Hydroxylase ERK MEK Reactive Oxygen Species (ROS) Apoptosis Caspase
MO-2097 is a RAF-1/HIF-1α inhibitor. MO-2097 induces RAF-1 destabilization, leading to a reduction in EMT-associated transcription factors and mesenchymal markers. MO-2097 inhibits HIF-1a protein expression mediated by hnRNPA2B1 under hypoxic and mimetic hypoxia. MO-2097 induces mitochondrial ROS, which leads to apoptosis in cells. MO-2097 effectively suppresses colorectal cancer metastasis by inhibiting the *RAF/MEK/ERK* signaling pathway. MO-2097 attenuates tumor growth in a xenograft HCT116 cell mouse model. MO-2097 can be used for the study of colorectal cancer .

HY-N1930

(-)-Hinesol Hinesol	Structural Classification Terpenoids Sesquiterpenes Plants Compositae Erythrina sigmoidea Hua	Apoptosis
(-)-Hinesol (Hinesol) is a potent anticancer agent. (-)-Hinesol induces apoptosis and cell cycle arrest at G0/G1 phase. (-)-Hinesol downregulates MEK/ERK pathway and NF-κB pathway and mediates theexpression of cyclin D1, Bax and Bcl-2. (-)-Hinesol has the potential for the research of non–small cell lung cancer .

HY-107417

Hypothemycin	Monophenols Microorganisms Antifungal Macrolide Antibiotics Classification of Application Fields Antibiotics Phenols Disease Research Disease Research Fields Source Classification Cancer	VEGFR MEK FLT3 PDGFR ERK
Hypothemycin, a fungal polyketide, is a multikinase inhibitor with K_is of 10/70 nM, 17/38 nM, 90 nM, 900 nM/1.5 μM, and 8.4/2.4 μM for VEGFR2/VEGFR1, *MEK1/MEK2, FLT-3, PDGFRβ/PDGFRα, and ERK1/ERK2*, respectively .

HY-N0103A

Sophocarpine monohydrate 10+ Cited Publications	Infection Alkaloids Piperidine Alkaloids Classification of Application Fields Leguminosae Sophora japonica L. Plants Inflammation/Immunology Disease Research Fields Source Classification	Autophagy Apoptosis NF-κB PI3K Akt MEK ERK
Sophocarpine monohydrate is a PTEN activator and an inhibitor of PI3K/Akt, MEK/ERK, and NF-κB signaling pathways. Sophocarpine monohydrate upregulates PTEN expression and inhibits PI3K/Akt phosphorylation, arrests tumor cell cycle and induces apoptosis. Sophocarpine monohydrate inhibits MEK/ERK phosphorylation and VEGF secretion, reducing tumor cell migration. Sophocarpine monohydrate can also inhibit NF-κB activation and p38 and JNK phosphorylation, reduce the expression of inflammatory factors such as iNOS and COX-2, and activate the Nrf2/HO-1 pathway to reduce oxidative stress. Sophocarpine monohydrate has anti-tumor, anti-inflammatory, antioxidant and anti-apoptotic effects, and can be used in the research of cancers such as glioblastoma and colorectal cancer, inflammation-related diseases, and Doxorubicin (HY-15142A)-induced cardiac damage .

HY-13425R

Deguelin (Standard) (-)-Deguelin (Standard); (-)-cis-Deguelin (Standard)	Structural Classification Flavonoids Leguminosae Isoflavanones Derris trifoliata Lour. Plants Source Classification	Akt Autophagy Apoptosis Reference Standards
Deguelin (Standard) is the analytical standard of Deguelin. This product is intended for research and analytical applications. Deguelin, a naturally occurring rotenoid, acts as a chemopreventive agent by blocking multiple pathways like PI3K-Akt, IKK-NF-κB, and MAPK-mTOR-survivin-mediated apoptosis. Deguelin binding to Hsp90 leads to a decreased expression of numerous oncogenic proteins, including MEK1/2, Akt, HIF1α, COX-2, and NF-κB.

HY-113632

Debromohymenialdisine 10Z-Debromohymenialdisine	Structural Classification Alkaloids Pyrrole Alkaloids Classification of Application Fields Marine natural products Sponge Disease Research Fields Cancer	Raf MEK
Debromohymenialdisine (10Z-Debromohymenialdisine) is a pyrrole alkaloid. Debromohymenialdisine has moderate inhibitory activity with an IC₅₀ value of 881 nM in the initial *Raf/MEK-1/MAPK* signaling cascade assay. Debromohymenialdisine can be used for the research of proliferation and differentiation .

HY-N0776R

Isorhamnetin (Standard) 3'-Methylquercetin (Standard)	Cardiovascular Disease Classification of Application Fields Hippophaë rhamnoides Plants Endogenous metabolite Flavonoids Leguminosae Elaeagnaceae Phenols Glycyrrhiza uralensis Fisch. Inflammation/Immunology Disease Research Fields Source Classification	Reference Standards MEK PI3K Endogenous Metabolite
Isorhamnetin (Standard) is the analytical standard of Isorhamnetin. This product is intended for research and analytical applications. Isorhamnetin is a flavonoid compound extracted from the Chinese herb Hippophae rhamnoides L.. Isorhamnetin suppresses skin cancer through direct inhibition of *MEK1* and PI3K.

HY-19700R

trans-Zeatin (Standard)	Structural Classification Natural Products Zea mays L. Gramineae Plants Endogenous metabolite Source Classification	Reference Standards MEK ERK Endogenous Metabolite
trans-Zeatin (Standard) is the analytical standard of trans-Zeatin. This product is intended for research and analytical applications. trans-Zeatin is a plant cytokinin, which plays an important role in cell growth, differentiation, and division; trans-Zeatin also inhibits UV-induced MEK/ERK activation.

HY-N12740

Napyradiomycin B4	Natural Products Microorganisms Source Classification	MEK ERK
Napyradiomycin B4 is a Napyradiomycin derivative, which inhibits the RANKL-induced *MEK-ERK* signaling pathway. Napyradiomycin B4 attenuates osteoclastogenesis and prevents alveolar bone destruction in experimental periodontitis .

HY-W065835

2-Bromoaldisine	Alkaloids Pyrrole Alkaloids Marine natural products Source Classification	HIV
2-Bromoaldisine is a pyrrole alkaloid that can be isolated from the Red Sea: marine sponge Stylissa carter. 2-Bromoaldisine inhibits HIV-1 vector infection. 2-Bromoaldisine inhibits *Raf/MEK/MAPK* pathway .

HY-N0103R

Sophocarpine (Standard)	Alkaloids Piperidine Alkaloids Structural Classification Leguminosae Sophora flavescens Aiton Plants Source Classification	Reference Standards Autophagy Apoptosis NF-κB PI3K Akt MEK ERK
Sophocarpine (Standard) is the analytical standard of Sophocarpine (HY-N0103). This product is intended for research and analytical applications. Sophocarpine is a PTEN activator and an inhibitor of PI3K/Akt, MEK/ERK, and NF-κB signaling pathways. Sophocarpine upregulates PTEN expression and inhibits PI3K/Akt phosphorylation, arrests tumor cell cycle and induces apoptosis. Sophocarpine inhibits MEK/ERK phosphorylation and VEGF secretion, reducing tumor cell migration. Sophocarpine can also inhibit NF-κB activation and p38 and JNK phosphorylation, reduce the expression of inflammatory factors such as iNOS and COX-2, and activate the Nrf2/HO-1 pathway to reduce oxidative stress. Sophocarpine has anti-tumor, anti-inflammatory, antioxidant and anti-apoptotic effects, and can be used in the research of cancers such as glioblastoma and colorectal cancer, inflammation-related diseases, and Doxorubicin (HY-15142A)-induced cardiac damage .

HY-128393R

Trilinolein (Standard)	Structural Classification Natural Products Panax notoginseng (Burkill) F. H. Chen ex C. H. Chow Plants Endogenous metabolite Araliaceae Source Classification	Reference Standards PI3K Akt E-Selectin Apoptosis MMP MEK ERK
Trilinolein (Standard) is the analytical standard of Trilinolein (HY-128393). This product is intended for research and analytical applications. Trilinolein is an orally active triglyceride that inhibits the PI3K/Akt, *Ras/MEK/ERK* signaling pathways, and MMP-2. Trilinolein can reduce oxidative stress, induce apoptosis, and inhibit cell migration. Trilinolein can be used in the research fields of cardiovascular disease, cerebrovascular disease (such as cerebral ischemia), and non-small cell lung cancer .

HY-N3628

Coronarin A	Hedychium coronarium Koen. Structural Classification Terpenoids Diterpenoids Plants Zingiberaceae	mTOR Ribosomal S6 Kinase (RSK)
Coronarin A is an orally active natural compound that inhibits mTORC1 and S6K1 to increase IRS1 activity. Coronarin A shows anti-inflammatory activity and can also be used for type 2 diabetes mellitus research .

HY-108635R

C16-PAF (Standard) PAF (C16) (Standard)	Structural Classification Natural Products Human Gut Microbiota Metabolites Endogenous metabolite Source Classification	p38 MAPK MEK ERK Endogenous Metabolite Reference Standards
C16-PAF (Standard) is the analytical standard of C16-PAF. This product is intended for research and analytical applications. C16-PAF (PAF (C16)), a phospholipid mediator, is a platelet-activating factor and ligand for PAF G-protein-coupled receptor (PAFR). C16-PAF exhibits anti-apoptotic effect and inhibits caspase-dependent death by activating the PAFR. C16-PAF is a potent MAPK and MEK/ERK activator. C16-PAF induces increased vascular permeability .

HY-N0442R

5-O-Methylvisammioside (Standard) 4'-O-β-D-Glucosyl-5-O-methylvisamminol (Standard)	Structural Classification Ophryosporus axilliflorus Hieron. Ketones, Aldehydes, Acids Umbelliferae Plants Source Classification	Reference Standards p38 MAPK Reactive Oxygen Species (ROS) TNF Receptor MEK ERK VEGFR Src Amyloid-β Anaplastic lymphoma kinase (ALK) NF-κB NOD-like Receptor (NLR) JNK Ferroptosis
5-O-Methylvisammioside (4'-O-β-D-Glucosyl-5-O-methylvisamminol) (Standard) is the analytical standard of 5-O-Methylvisammioside. This product is intended for research and analytical applications. 5-O-Methylvisammioside is an orally active natural chromone glycoside and multiple biological activities. 5-O-Methylvisammioside inhibits ferroptosis by activating the Nrf2/HO-1 signaling axis. 5-O-Methylvisammioside alleviates intestinal barrier damage by inhibiting the ROS/NF-κB/NLRP3 pathway. 5-O-Methylvisammioside exerts a protective effect against acute liver injury by reducing ALT/AST, decreasing inflammatory infiltration, and inhibiting IκB-α phosphorylation and NF-κB nuclear translocation. 5-O-Methylvisammioside blocks the *HMGB1/RAGE/MEK/ERK* signaling axis to exert anti-tumor and anti-angiogenic effects. 5-O-Methylvisammioside improves depression-like behaviors by inhibiting Src kinase and the NF-κB pathway.

HY-N0392R

Polygalasaponin F (Standard)	Triterpenes Structural Classification Terpenoids Polygalaceae Polygala japonica Houtt. Plants Source Classification	Reference Standards Toll-like Receptor (TLR) PI3K Akt NF-κB
Polygalasaponin F (Standard) is the analytical standard of Polygalasaponin F. This product is intended for research and analytical applications. Polygalasaponin F is an orally active triterpenoid saponin monomer. Polygalasaponin F downregulates the expression of Bax, p53, caspase-3, NF-κB p65 and *MEK1; restores and upregulates the expression of Bcl-2; activates the PI3K/Akt* signaling pathway; inhibits the phosphorylation of p38 MAPK, nuclear translocation of NF-κB, TLR4-mediated signaling pathway, mitophagy (Mitophagy) and ROS production; enhances cell viability and suppresses apoptosis (Apoptosis). Polygalasaponin F maintains mitochondrial function, alleviates Ca ²⁺ overload, upregulates pCREB and BDNF, preserves cell viability and inhibits the release of inflammatory cytokines. Polygalasaponin F alleviates lung injury induced by influenza A H1N1 and cerebral ischemia-reperfusion injury. Polygalasaponin F is applicable to researches related to Parkinson's disease, cerebral ischemia, pneumonia induced by influenza A H1N1, stroke and Alzheimer's disease.

HY-N9980

Antcin K	Structural Classification Microorganisms Steroids Source Classification	PI3K Akt NF-κB p38 MAPK AP-1
Antcin K is a selective inhibitor targeting the PI3K/Akt, NF-κB, *MEK1/2-ERK, p38* and AP-1 pathways. Antcin K upregulates IL-10 expression, thereby inhibiting the production of pro-inflammatory factors, blocking monocyte adhesion, reducing tissue damage, and promoting myogenesis. Antcin K has significant anti-inflammatory, anti-damage and tissue protective activities. Antcin K is mainly used in the research of inflammation-related diseases such as periodontitis, rheumatoid arthritis, and skeletal muscle injury .

Cat. No.	Product Name	Chemical Structure

HY-19700S

trans-Zeatin-d5
trans-Zeatin-d₅ is deuterium labeled trans-Zeatin. trans-Zeatin is a plant cytokinin, which plays an important role in cell growth, differentiation, and division; trans-Zeatin also inhibits UV-induced MEK/ERK activation.

HY-B0185S1

Lidocaine-d10

Lidocaine-d₁₀ is the deuterium labeled Lidocaine. Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence . Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia .

HY-10999S

Trametinib-d4
Trametinib-d₄ is the deuterium labeled Trametinib. Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC₅₀s of about 2 nM. Trametinib activates autophagy and induces apoptosis .

HY-B0185AS

Lidocaine-d10 hydrochloride

Lidocaine-d₁₀ (hydrochloride) is the deuterium labeled Lidocaine hydrochloride. Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits sodium channels involving complex voltage and using dependence . Lidocaine hydrochloride decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride, an amide derivative, has the potential for the research of the ventricular arrhythmia .

HY-13064S1

Cobimetinib-d4 hydrochloride
Cobimetinib-d₄ hydrochloride is deuterated labeled Cobimetinib (HY-13064). Cobimetinib (GDC-0973, RG7420) is a potent, selective and oral *MEK1* inhibitor with an IC₅₀ of 4.2 nM for *MEK1*.

HY-B0185AS1

Lidocaine-d6 hydrochloride

Lidocaine-d₆ (hydrochloride) is deuterium labeled Lidocaine (hydrochloride). Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits sodium channels involving complex voltage and using dependence . Lidocaine hydrochloride decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine hydrochloride is an amide derivative and a agent to treat ventricular arrhythmia and an effective tumor-inhibitor .

HY-10999S1

Trametinib-13C6
Trametinib- ¹³C₆ is the ¹³C-labeled Trametinib. Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC₅₀s of about 2 nM. Trametinib activates autophagy and induces apoptosis .

HY-10999S2

Trametinib-13C,d3
Trametinib- ¹³C,d₃ is the ¹³C- and deuterium labeled Trametinib. Trametinib (GSK1120212; JTP-74057) is an orally active MEK inhibitor that inhibits MEK1 and MEK2 with IC₅₀s of about 2 nM. Trametinib activates autophagy and induces apoptosis .

HY-B0185S

Lidocaine-d10 N-Oxide

N-Oxide Lidocaine-d₁₀ is the deuterium labeled Lidocaine. Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence . Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia .

HY-15202S3

Binimetinib-d4
Binimetinib-d₄ (MEK162-d₄) is deuterium labeled Binimetinib. Binimetinib (MEK162) is an oral and selective *MEK1/2* inhibitor. Binimetinib (MEK162) inhibits *MEK* with an IC₅₀ of 12 nM.

HY-15202S1

Binimetinib-d3
Binimetinib-d₃ (MEK162-d₃) is deuterium labeled Binimetinib. Binimetinib (MEK162) is an oral and selective *MEK1/2* inhibitor. Binimetinib (MEK162) inhibits *MEK* with an IC₅₀ of 12 nM .

HY-13078S

Cobimetinib-13C6 racemate
Cobimetinib- ¹³C₆ (GDC-0973- ¹³C₆; XL518- ¹³C₆) racemate is the deuterium labeled Cobimetinib (racemate) (HY-13078) . Cobimetinib racemate (GDC-0973 racemate; XL518 racemate) is the racemate of Cobimetinib. Cobimetinib is a potent and selective MEK inhibitor .

HY-32718S

Pelitinib-d6
Pelitinib-d₆ (EKB-569-d₆) is the deuterium labeled Pelitinib. Pelitinib (EKB-569) is an irreversible inhibitor of EGFR with an IC₅₀ of 38.5 nM; also slightly inhibits Src, MEK/ERK and ErbB2 with IC₅₀s of 282, 800, and 1255 nM, respectively .

HY-B0185S2

Lidocaine-d6

Lidocaine-d₆ (Lignocaine-d₆) is deuterium labeled Lidocaine. Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence . Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of MEK/ERK and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia .

HY-128393S1

Trilinolein-13C54

Trilinolein- ¹³C₅₄ is the ¹³C-labeled Trilinolein (HY-128393). Trilinolein is an orally active triglyceride that inhibits the PI3K/Akt, Ras/MEK/ERK signaling pathways, and MMP-2. Trilinolein can reduce oxidative stress, induce apoptosis, and inhibit cell migration. Trilinolein can be used in the research fields of cardiovascular disease, cerebrovascular disease (such as cerebral ischemia), and non-small cell lung cancer .

HY-P0119S

Lixisenatide (Leu-13C6,15N) TFA

Lixisenatide (Leu- ¹³C₆, ¹⁵N) TFA is the ¹³C- and ¹⁵N-labeled Lixisenatide (HY-P0119). Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Lixisenatide inhibits the inflammatory response through down regulation of pro-inflammatory cytokines, and suppresses of the Akt-MEK1/2 signaling pathway. Lixisenatide can inhibit oxidative stress, mitochondrial dysfunction and apoptosis. Lixisenatide can be used for the researches of inflammation, metabolic disease, neurological disease and cardiovascular disease, such as rheumatoid arthritis, diabetes, Alzheimer's disease and atherosclerosis .

HY-159846S

Luvometinib-d
Luvometinib-d is the deuterium labeled Luvometinib (HY-159846). Luvometinib is a mitogen-activated protein kinase (MEK) inhibitor with antitumor activity .

HY-128393S2

Trilinolein-d5

Trilinolein-d₅ is the deuterium labeled Trilinolein (HY-128393). Trilinolein is an orally active triglyceride that inhibits the PI3K/Akt, Ras/MEK/ERK signaling pathways, and MMP-2. Trilinolein can reduce oxidative stress, induce apoptosis, and inhibit cell migration. Trilinolein can be used in the research fields of cardiovascular disease, cerebrovascular disease (such as cerebral ischemia), and non-small cell lung cancer .

Targets Recommended: MEK ASK1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10254G

Mirdametinib 1 Publications Verification PD0325901; PD325901	MEK	Cancer
Mirdametinib (PD0325901) (GMP) is Mirdametinib (HY-10254) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Mirdametinib is an orally active, selective and non-ATP-competitive *MEK* inhibitor .

HY-B0185G

Lidocaine Lignocaine	Apoptosis Sodium Channel MEK ERK NF-κB	Cancer
Lidocaine (GMP) is Lidocaine (HY-B0185) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Lidocaine inhibits sodium channels involving complex voltage and using dependence . Lidocaine decreases growth, migration and invasion of gastric carcinoma cells via up-regulating miR-145 expression and further inactivation of *MEK/ERK* and NF-κB signaling pathways. Lidocaine is an amide derivative and has potential for the research of ventricular arrhythmia .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks